Susanta Samajdar serves as the Chief Scientific Officer at Aurigene Oncology Limited, bringing over 25 years of experience in synthetic and medicinal chemistry research within diverse sectors of Indian industries and academia. He earned his Ph.D. in Synthetic Organic Chemistry from the Indian Association for the Cultivation of Science (IACS) in Kolkata. Subsequently, he pursued post-doctoral training in anti-cancer drug discovery at MD Anderson Cancer Centre in Houston, TX.

Dr. Samajdar has spearheaded multi-disciplinary drug discovery teams, resulting in the successful delivery of more than 15 preclinical development candidates spanning the Oncology and Inflammation therapeutic domains. His proficiency extends across various therapeutic modalities, encompassing small molecules, antibodies, antibody drug conjugates (ADCs), protein degradation, and natural products.

He has tackled a range of target classes such as transcription factors, GPCRs, ion channels, proteases, kinases, NHRs, epigenetic effector proteins etc. With a prolific track record, Dr. Samajdar has amassed over 100 patents and publications. He has been affiliated with Aurigene since March 2012, contributing his expertise in anti-cancer drug discovery and exploring newer avenues in Oncology research.